When does Bradley Hauser’s 27,000-share AMIX restricted stock award vest?

The filing states that the 27,000-share restricted stock award vests one year from the date of issuance of September 3, 2026. The full award is therefore scheduled to vest one year after that issuance date, as disclosed.

Autonomix CEO granted 27,000 restricted shares

Q: What equity award did AMIX grant to its CEO Bradley Hauser?

Autonomix Medical granted CEO Bradley Hauser a restricted stock award of 27,000 shares of Common Stock on September 3, 2026, reported as a grant or award acquisition on a Form 4.

Q: Was the AMIX CEO’s September 3, 2026 transaction a purchase or a grant?

It was reported as a grant, award, or other acquisition of 27,000 shares of Common Stock, coded as a Form 4 transaction type corresponding to an equity grant rather than an open-market purchase.

Q: Was the AMIX CEO’s restricted stock grant made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is unchecked, and no footnote indicates that the September 3, 2026 restricted stock grant to the CEO was made pursuant to a Rule 10b5-1 trading plan.

Autonomix Medical granted its CEO a 27,000-share restricted stock award vesting one year after issuance.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Autonomix Medical, Inc. (symbol: AMIX) is the issuer of record for a Form 4 filing submitted to the SEC. Hauser Bradley reported acquisition or exercise transactions in this Form 4 filing.

Autonomix Medical, Inc. (AMIX) reported that CEO and President Bradley Hauser received an equity grant of 27,000 shares of Common Stock on September 3, 2026. The award is described as a restricted stock award vesting one year from the date of issuance of September 3, 2026, and is held as direct ownership. No Rule 10b5-1 trading plan is reported for this grant.

Insider Trade Summary

Grant/Award: 27,000 shares

Grant/Award 1 txn

Insider Hauser Bradley

Role CEO and President

Type	Security	Shares	Price	Value
Grant/Award	Common Stock ^F1	27,000	--	--

Holdings After Transaction: Common Stock — 27,000 shares (Direct)

Footnotes (1)

F1. Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026.

Key Figures

Restricted stock award: 27,000 shares of Common Stock Shares owned after transaction: 27,000 shares Number of acquisition transactions: 1 transaction +1 more

4 metrics

Restricted stock award 27,000 shares of Common Stock Grant to CEO and President Bradley Hauser on September 3, 2026

Shares owned after transaction 27,000 shares Direct ownership position following the reported grant

Number of acquisition transactions 1 transaction Form 4 transaction summary for September 3, 2026

Vesting schedule One year from September 3, 2026 Restricted stock award vesting period as described in the footnote

Key Terms

restricted stock award, Rule 10b5-1 trading plan, direct ownership

3 terms

restricted stock award financial

"Represents restricted stock award vesting one-year from the date of issuance"

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

Rule 10b5-1 trading plan regulatory

"No Rule 10b5-1 trading plan is reported for this grant"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

direct ownership financial

"and is held as direct ownership"

FAQ

What equity award did AMIX grant to its CEO Bradley Hauser?

Autonomix Medical granted CEO Bradley Hauser a restricted stock award of 27,000 shares of Common Stock on September 3, 2026, reported as a grant or award acquisition on a Form 4.

How many AMIX shares does Bradley Hauser directly own after this Form 4 transaction?

After this reported grant, Bradley Hauser is shown as directly owning 27,000 shares of Autonomix Medical Common Stock, matching the size of the restricted stock award reported in the Form 4.

Was the AMIX CEO’s September 3, 2026 transaction a purchase or a grant?

It was reported as a grant, award, or other acquisition of 27,000 shares of Common Stock, coded as a Form 4 transaction type corresponding to an equity grant rather than an open-market purchase.

Was the AMIX CEO’s restricted stock grant made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is unchecked, and no footnote indicates that the September 3, 2026 restricted stock grant to the CEO was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/08/2026 - 04:20 PM Accepted by SEC EDGAR 09/08/2026 - 04:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hauser Bradley

(Last)

(First)

(Middle)

C/O AUTONOMIX MEDICAL, INC.

21 WATERWAY AVENUE, SUITE 300

(Street)

THE WOODLANDS

TEXAS

77380

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Autonomix Medical, Inc. [ AMIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/03/2026		A		27,000	A	⁽¹⁾	27,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026.

	/s/ Trent Smith, Attorney-in-Fact for Brad Hauser	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Autonomix CEO granted 27,000 restricted shares

Rhea-AI Filing Summary

Positive

Negative